FJORD DIAGNOSTICS SDN BHD of Kuala Lumpur at MEDICA 2019 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option

FJORD DIAGNOSTICS SDN BHD

49, Jalan Puteri 5/8, Puchong, 47100 Kuala Lumpur
Malaysia
Telephone +60 3 80613199
Fax +60 3 80685382
enquiries@fjorddiagnostics.com

This company is co-exhibitor of
Malaysia External Trade Development Corporation (MATRADE)

Hall map

MEDICA 2019 hall map (Hall 17): stand A10

Fairground map

MEDICA 2019 fairground map: Hall 17

Our range of products

Product categories

  • 03  Diagnostic Tests
  • 03.03  Haematology / histology / cytology testing
  • 03.03.04  Other haematology / histology / cytology testing

Other haematology / histology / cytology testing

About us

Company details

Fjord Diagnostics is an innovative company in the field of medical diagnostics, applying assay technologies to commercial use. With the commitment to provide better and affordable alternatives in pathological and clinical laboratory testing, we are dedicated to technology breakthrough and product innovation.

Having a complete operation chain from R&D, manufacturing to sales & marketing, we serve the medical diagnostic industry with uncompromised service and product quality. Our manufacturing is operated under the strict GMP & ISO 13485 certified standards.

At present, our core business operation focuses on a range of cytology products, ranging for cervical sampling devices to state-of-the-art dual filtration automated CY-PREP® Pap Test System for processing of liquid based cytology.

In 2018, the company has developed its unique proprietary patented Reverse Filtration Process Technology platform, with possible application in the field of Urinalysis, Cytology, Microbiology, and Life Science.

The major advantage of the Reverse Filtration Process over the existing Dead-End Filtration Process, Cross-Flow Filtration Process and Dynamic Filtration Process, is that membrane fouling (clogging) is brought to a minimum.

In product development, the company has line up a few major products development using its proprietary Reverse Filtration Process Technology platform. The first commercial product to be released from this technology platform will be the much awaited Urine Sediment Microscopy Test, follow by other sample preparation procedure test like Tuberculosis Test, Non-Gynae Cytology, etc, which will improve the diagnostic accuracy of these tests and simplify the way these tests are performed in the pathological and clinical laboratory setting.

More Less